ZYME has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZYME has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Zymeworks's Net Cash per Share for the quarter that ended in Mar. 2024 was $3.25.
The historical rank and industry rank for Zymeworks's Net Cash per Share or its related term are showing as below:
During the past 10 years, the highest Price-to-Net-Cash Ratio of Zymeworks was 10.19. The lowest was 1.47. And the median was 4.17.
The historical data trend for Zymeworks's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Cash per Share | Get a 7-Day Free Trial | 4.46 | 6.47 | 2.41 | 5.34 | 3.68 |
Zymeworks Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Net Cash per Share | Get a 7-Day Free Trial | 3.33 | 2.76 | 2.41 | 3.68 | 3.25 |
For the Biotechnology subindustry, Zymeworks's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zymeworks's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Zymeworks's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Zymeworks's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
Net Cash per Share (A: Dec. 2023 ) | |||||||
= | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (374.327 | - | 116.074 | - | 0) | / | 70.116 |
= | 3.68 |
Zymeworks's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as
Net Cash per Share (Q: Mar. 2024 ) | = | (Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | - | Minority Interest) | / | Shares Outstanding (EOP) |
= | (345.047 | - | 115.753 | - | 0) | / | 70.5682 |
= | 3.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (NAS:ZYME) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Thank you for viewing the detailed overview of Zymeworks's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Andrew Moore | officer: Chief Scientific Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Christopher Astle | officer: SVP & Chief Financial Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Kenneth Galbraith | director, officer: Chair & CEO | OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
Carlos Campoy | director | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Miller Derek John Michael | director | 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709 |
Neil A Klompas | officer: President & COO | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
Troy Cox | director | C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141 |
Kenneth J. Hillan | director | C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080 |
Hollings Renton | director | |
Kelvin Neu | director | 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014 |
Natalie Sacks | director | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Neil Josephson | officer: Chief Medical Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
From GuruFocus
By Business Wire Business Wire • 12-14-2022
By sperokesalga sperokesalga • 05-18-2023
By Marketwired • 07-19-2023
By Business Wire Business Wire • 01-04-2023
By Business Wire Business Wire • 10-20-2022
By Marketwired • 07-03-2023
By Marketwired • 08-01-2023
By Business Wire Business Wire • 12-19-2022
By sperokesalga sperokesalga • 06-01-2023
By Marketwired • 06-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.